What factors guide the sponsor's audit plan for a clinical trial?

• A. Random site selection without risk assessment.
• B. The sponsor's internal preferred vendor list only.
• C. Budget constraints alone.
• D. The importance of the trial to regulatory submissions, number of participants, trial complexity, level of risks to participants, and any identified problems.

Answer: (D)

Audits in a clinical trial are guided by a risk-based approach that focuses on protecting participants and ensuring reliable data. The sponsor’s audit plan should be shaped by factors that affect safety, data integrity, and regulatory compliance. This means giving attention to how important the trial is for regulatory submissions, how many participants are involved, how complex the trial is, the level of risk to participants, and any problems already identified. These elements determine where audits should concentrate, how often they should occur, and how broad their scope should be, so resources are used where they matter most.

Why this set of factors is the best guide is that they directly influence critical processes and outcomes: pivotal trials for submissions require rigorous oversight; larger or more complex studies with higher participant risk demand more thorough audits of key activities like consent, safety reporting, data handling, and trial conduct. If problems are already identified, that area warrants heightened scrutiny. In contrast, random site selection without risk assessment, relying only on internal vendor lists, or budgeting alone don’t address quality and safety concerns and could miss significant risk areas.